Cognition Therapeutics CEO to Present Alzheimer's and DLB Progress at Upcoming Conferences
核心洞察
Cognition Therapeutics (搜索) CEO Lisa Ricciardi will discuss progress in Alzheimer's and dementia with Lewy body (搜索) (DLB) programs at upcoming conferences.
Positive topline results from the Phase 2 SHIMMER study in DLB patients will be presented at the International Lewy Body Dementia Conference.
Cognition is preparing for an end-of-Phase 2 meeting with the FDA to review results from the SHINE study in mild-to-moderate Alzheimer’s disease (搜索).
Cognition Therapeutics (搜索) CEO Lisa Ricciardi is set to present the company's advancements in Alzheimer's disease and dementia with Lewy bodies (DLB) at upcoming conferences during the week of the JP Morgan Healthcare Conference 2025. The presentations will highlight positive topline results from the Phase 2 SHIMMER study in DLB and preparations for an FDA meeting regarding the SHINE study in Alzheimer's.
Ricciardi stated, "I am looking forward to these opportunities to discuss the incredible progress we have made in 2024 with our Alzheimer’s and dementia with Lewy body (搜索) (DLB) programs. We capped off 2024 with positive topline results from our Phase 2 SHIMMER study in patients with DLB and are looking forward to presenting these findings at the International Lewy Body Dementia Conference at the end of January in Amsterdam. We are preparing now for our end-of-Phase 2 meeting with the FDA to review results from our SHINE study in mild-to-moderate Alzheimer’s disease (搜索), an important regulatory milestone. In addition, we received clearance for the generic name for our candidate, CT1812, which will be called zervimesine (搜索)."
Conference Participation
Ricciardi will participate in the Longwood Healthcare Leaders Stanford Summit on January 11, 2025, moderating a panel on accelerating drug development. Following this, she will attend the Sachs 8th Annual Neuroscience Innovation Forum on January 12, 2025, participating in a panel on innovation in AD/PD and other cognitive disorders and delivering a corporate presentation.
Zervimesine (CT1812) Development
Cognition Therapeutics (搜索) is focused on developing small molecule therapeutics for age-related degenerative disorders. Their lead candidate, zervimesine (搜索) (formerly CT1812), is currently under investigation in clinical programs for Alzheimer’s disease (搜索), DLB, and dry age-related macular degeneration (dry AMD). The company believes zervimesine and their pipeline of σ-2 receptor modulators can regulate pathways impaired in these diseases, offering a distinct approach from other treatments.
About Cognition Therapeutics
Cognition Therapeutics (搜索), Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative treatments for degenerative disorders of the central nervous system and retina. Their research focuses on σ-2 receptor modulators and their potential to address unmet needs in diseases like Alzheimer's and DLB.